Astellas Pharma

CRESEMBA

Manufacturer:

Astellas Pharma

Cresemba HCPCS:

J1833

HCPCS Code Descriptor:

Injection, isavuconazonium, 1 mg

Category:

J Code

Cresemba NDCs:

00469-0420-99, 00469-0420-01

Primary Type:

Anti-Fungal

Generic/Specialty Status:

Single-Source

Route of Administration:

Intravenous

Potential NDC Listing Errors:

Our team did not identify any potential listing errors/discrepancies for the NDCs mapped to this HCPCS code.

About Cresemba:

CRESEMBA is an Anti-Fungal drug manufactured by Astellas Pharma and administered via the Intravenous route of administration. The J Code: J1833 is aligned to the drug CRESEMBA.

Cresemba is an antifungal medicine used to treat certain types of fungal infections. Cresemba may be given to patients with invasive fungal infections caused by either invasive aspergillosis or mucormycosis. Cresemba's active ingredient, isavuconazole, is thought to work by interrupting the formation of ergosterol, which is an important component of fungal cell membranes. This is thought to kill the fungus and stop the spread of infection. Cresemba is available as both a capsule, and as an injection.

ACCESS PRICING AND MORE BY REGISTERING

J1833 Added Date:

January 1, 2016

J1833 Effective Date:

January 1, 2016

J1833 Termination Date:

HCPCS Active

Cresemba billing and coding information can be found through Astellas Pharma at the link below:
Cresemba patient assistance information can be found through Astellas Pharma’s Support Solutions at the URL: http://www.astellaspharmasupportsolutions.com/products/cresemba/index.aspx
CRESEMBA prescribing information can be found at the link below:
Information regarding CRESEMBA’s side effects can be found at MedlinePlus